Investing in its cancer and haematological portfolio, Jazz Pharmaceuticals has partnered up with Codiak Biosciences to develop exosome therapeutics in a deal worth US$1.1 B. Using Codiak’s engEx™ precision engineering platform, the companies will develop five therapies targeting oncogenes that are undruggable with current modalities, including neuroblastoma -RAS and signal transducer and activator of transcription 3. Preclinical data showed that selective delivery of a therapeutic resulted in significantly improved potency and reduced toxicity.